{"id":"W2992194132","doi":"10.1007/s12079-019-00542-6","title":"Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis","year":2019,"lang":"en","type":"article","venue":"Journal of Cell Communication and Signaling","topic":"Connective Tissue Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Nintedanib; Pirfenidone; Medicine; Idiopathic pulmonary fibrosis; Tolerability; Clinical trial; Vital capacity; Internal medicine; Intensive care medicine; Lung; Adverse effect; Diffusing capacity; Lung function","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002100358,0.0003830047,0.0006183079,0.0002395283,0.0007174395,0.001128497,0.0008027251,0.004687684,0.001808947],"category_scores_gemma":[0.004102646,0.0001249697,0.0004477945,0.0002164233,0.001008519,0.0007544017,0.0003900773,0.004090946,0.001364972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009006312,"about_ca_system_score_gemma":0.001146169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001122119,"about_ca_topic_score_gemma":0.004229392,"domain_scores_codex":[0.998912,0.000299806,0.000130482,0.0001647719,0.0003818987,0.0001110825],"domain_scores_gemma":[0.9985263,0.000698187,0.0001761377,0.00003613702,0.0003387493,0.0002243429],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.001302478,0.00008867061,0.0008770919,0.0009997669,0.0000851955,0.001492226,0.0001954348,0.0002365695,0.01207066,0.005862025,0.7964303,0.1803596],"study_design_scores_gemma":[0.0001856246,0.0006680476,0.001876998,0.0003371969,0.0000768039,0.001326942,0.00009883565,0.0002969001,0.00459451,0.001899272,0.9886075,0.00003147394],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.01439089,0.09943632,0.003834264,0.6804889,0.1818631,0.0001187743,0.0004304912,0.0003153427,0.01912199],"genre_scores_gemma":[0.1044182,0.1029511,0.003633333,0.4820997,0.2423761,0.0001776393,0.0005415791,0.0001913863,0.0636109],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004687684,"threshold_uncertainty_score":0.01110792,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05069009097817694,"score_gpt":0.3877615938795685,"score_spread":0.3370715029013916,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}